key: cord-0868351-x7b1nvpq
authors: Lustig, Yaniv; Nemet, Ital; Kliker, Limor; Zuckerman, Neta; Yishai, Ruti; Alroy-Preis, Sharon; Mendelson, Ella; Mandelboim, Michal
title: Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
date: 2021-04-07
journal: N Engl J Med
DOI: 10.1056/nejmc2104036
sha: d26ff3735ff9d691c47431546e49d1022bfef3df
doc_id: 868351
cord_uid: x7b1nvpq

nan

To the Editor: The BNT162b2 vaccine was shown to have 95% efficacy against coronavirus disease 2019 (Covid-19). 1 To date, the two-dose vaccine protocol has not been approved in Israel for persons previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, administration of a single dose is now being considered.

In addition to the original virus first identified in Wuhan, China, SARS-CoV-2 variants first identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) have been de- Serum samples from six patients previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), obtained 1 to 12 weeks after natural infection, immediately before receiving one dose of the BNT162b2 vaccine, and 1 to 2 weeks after vaccination, were tested with a microneutralization assay for the neutralizing response 1.7 , B.1.351, and P.1 variants was performed on 18 serum samples from six health care workers previously infected with SARS-CoV-2, with a sample obtained from each patient at three time points: 1 to 12 weeks after natural infection, immediately before vaccination, and 1 to 2 weeks after vaccination (Table S1 in variants, respectively -that is, the titers after vaccination were 114, 203, 81, and 228 times as high as the titers immediately before vaccination ( Fig. 1 and Table S2 ).

This study showed that, in our small cohort, one vaccine dose substantially increased neutralizing activity against all variants tested, with similar titers detected across patients for each variant. This highlights the importance of vaccination even in previously infected patients, given the added benefit of an increased antibody response to the variants tested. Limitations of the study include the small cohort of only women and the lack of evaluation of T-cell response. However, we think the fact that all six patients responded similarly to vaccination supports our conclusions. Further studies could investigate the effects of a second vaccine dose on neutralizing activity against variants of concern in persons who have and persons who have not been previously infected. Yaniv Lustig, Ph.D. Ital Nemet, Ph.D. Limor Kliker, M.Sc. Neta Zuckerman, Ph.D.

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

SARS-CoV-2 variants and ending the COVID-19 pandemic

Neutralizing activity of BNT162b2-elicited serum -preliminary report

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Correspondence Copyright © 2021 Massachusetts Medical Society

This letter was published on April 7, 2021, at NEJM.org.